Reasonable question Lupe
We can only assume that the BOD is making progress towards gaining TGA approval for GAD later in the year maybe, but for now
"Clarion Clinics Group, the collaboration between Australia’s foremost clinical experts and IHL (84.5% owned by IHL subsidiary Psychennex Pty Ltd), will provide treatment under the TGA regulated authorised prescriber scheme, for the use of psilocybin for treatment-resistant depression (TRD) and the use of MDMA for PostTraumatic Stress Disorder (PTSD). A number of other depression and anxiety related disorders will be treated with ketamine-assisted psychotherapy"
https://stocknessmonster.com/announcements/ihl.asx-3A617110/
@Lupe it appears that the BOD are going to start with what has already been approved by the TGA
1. Psilocybin for TRD
2. MDMA for PTSD
I assume that once our trial for GAD is finalised then they will seek TGA approval for that indication also.
In the meantime, it's TGA-approved treatments first!
Good luck @Lupe
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Reasonable question LupeWe can only assume that the BOD is...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online